Breaking News

Merck KGaA, Darmstadt, Germany Acquires SpringWorks Therapeutics for $3.4M

Forms a rare tumor business for Merck KGaA, Darmstadt, Germany, including SpringWorks’ portfolio and pimicotinib.

Author Image

By: Charlie Sternberg

Associate Editor

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion. The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on April 28, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. “The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck KGaA, Darmstadt, Ger...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters